Report

Christmas comes early – Fundraising and Interims

RUA have announced a Placing and Open Offer conditional on shareholder approval at a General Meeting (GM) – our financials assume the full amount of £7m, less costs, is raised.

Since acquiring RUA Medical, RUA Life Sciences has become a fully integrated medical device designer and manufacturer. When the fundraising completes, RUA will have the resources to accelerate the development of its products on which much of our valuation has been based.

We have updated our valuation for the expectations of the full amount raised by the conditional placing and Open Offer, increased share count, and our forecast for FY21 revenues of RUA Medical revenues (now that they are incorporated into those of RUA Life Sciences).

Our valuation has increased to £115.2m from £112.3m. That equates to 523p per share (corrected from note sent 14 December).
Underlying
Rua Life Sciences Plc

Provider
Equity Development
Equity Development

​Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.

Analysts
Andy Smith

Other Reports on these Companies
Other Reports from Equity Development

ResearchPool Subscriptions

Get the most out of your insights

Get in touch